<DOC>
	<DOCNO>NCT00005857</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial compare effectiveness trastuzumab alone combination docetaxel treat patient metastatic prostate cancer refractory hormone therapy .</brief_summary>
	<brief_title>Trastuzumab Docetaxel Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy toxicity docetaxel ( arm I ) v trastuzumab ( Herceptin ) ( arm II ) , follow combination docetaxel trastuzumab patient androgen-independent hormone-refractory metastatic , Her2/neu-positive prostate cancer . ( Arm I close accrual effective 07/30/2001 . ) OUTLINE : This multicenter study . - Arm I : Patients receive docetaxel IV 1 hour weekly 6 week . Treatment continue every 8 week least 2 course absence unacceptable toxicity . ( Arm I close accrual effective 07/30/2001 . Arm I patient crossover arm II . ) - Arm II : Patients receive trastuzumab ( Herceptin ) IV 30-90 minute weekly 8 week . Treatment continue every 8 week least 2 course absence unacceptable toxicity . Patients progressive stable disease 2 course single-agent therapy receive docetaxel IV 1 hour day 1 week 6 consecutive week trastuzumab IV 30-90 minute day 1 week 8 consecutive week . Treatment continue every 8 week least 2 course absence disease progression unacceptable toxicity . Patients complete partial response single-agent therapy continue therapy experience progressive stable disease . The patient proceed combination therapy . Patients follow death . PROJECTED ACCRUAL : A total 108-160 patient ( 54-80 per treatment arm ) accrue study . ( Arm I close accrual effective 07/30/2001 . )</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV prostate cancer ( T , N , M1 , G ; D3 ) Clinical evidence metastatic disease bone soft tissue Her2/neupositive ( 2+ 3+ ) immunochemistry fluorescent situ hybridization Androgenindependent Serum PSA least 10 ng/mL risen 3 successive evaluation prior hormonal therapy At least 1 month since prior antiandrogen therapy ( e.g. , flutamide , bicalutamide , nilutamide ) rise PSA level 1 2 rise PSA level , measure least 2 week apart , antiandrogen withdrawal Bone disease elevate PSA alone allow LHRH analog therapy must continue patient prior orchiectomy castrate level testosterone PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm3 Absolute granulocyte count least 1,800/mm3 Platelet count least low limit normal ( LLN ) Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine great 1.6 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : Ejection fraction 50 % LLN MUGA scan 2D echocardiogram No symptomatic coronary artery disease No active ischemia EKG Other : Fertile patient must use effective contraception No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No one prior nonanthracycline chemotherapy regimen ( include suramin ) Endocrine therapy : See Disease Characteristics No concurrent corticosteroid antiemetic Radiotherapy : At least 4 week since prior radiotherapy At least 3 month since prior strontium chloride Sr 89 recover No concurrent radiotherapy measurable lesion Surgery : See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>